abstract |
The compounds of formula (I) and pharmaceutically acceptable salts thereof are useful, inter alia, for the treatment of MTAP-deficient pancreatic cancer, or MTAP-deficient esophageal cancer, such as MTAP-deficient lung cancer, or PDAC, such as NSCLC. and provides a therapeutic advantage when combined with the other agents as described herein compared to treatment when each agent is administered alone. |